HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Last Updated on: Apr 24, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1411 as of 23 Apr 15:30.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Dec '24 is ₹ 3418 crore as compare to the Sep '24 revenue of ₹ 3473 crore. This represent the decline of -1.57% The revenue of Lupin Ltd for the Dec '24 is ₹ 5821 crore as compare to the Sep '24 revenue of ₹ 5715 crore. This represent the growth of 1.86%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '24 is ₹ 631.36 crore as compare to the Sep '24 ebitda of ₹ 641.33 crore. This represent the decline of -1.55% The ebitda of Lupin Ltd for the Dec '24 is ₹ 1409 crore as compare to the Sep '24 ebitda of ₹ 1382 crore. This represent the growth of 1.95%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 348.03 crore over 7 quarters. This represents a CAGR of 49.03% The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 858.86 crore over 7 quarters. This represents a CAGR of 44.07% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 1.37 % on March 2024 . This represents a CAGR of -23.44% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.
  • The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland.

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.
  • In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharma's US arm set to launch generic Adderall tablets

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroampheta...

Read more

17 Apr 2025 08:04

News

Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the p...

Read more

17 Apr 2025 20:08

News

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphe...

Read more

16 Apr 2025 19:53

News

Glenmark Pharmaceuticals Ltd slips for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quot...

Read more

11 Apr 2025 13:35

News

Glenmark Pharmaceuticals announces change in senior management

Glenmark Pharmaceuticals has appointed Anurag Mantri as President (Senior Management Perso...

Read more

07 Apr 2025 09:00

News

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochlo...

Read more

01 Apr 2025 09:40

Lupin Ltd News Hub

News

Lupin gets EIR from USFDA for Nagpur facility

The EIR was issued following an inspection of the facility conducted from 10 June to 13 Ju...

Read more

17 Apr 2025 15:00

News

Lupin allots 24,101 equity shares under ESOP

Lupin has allotted 24,101 equity shares under ESOP on 21 March 2025. In view of the above,...

Read more

21 Mar 2025 16:10

News

Nanomi wins prestigious CMO Award for Life Science Leadership in Drug Delivery

Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin, today announced that it ...

Read more

21 Mar 2025 19:12

News

Lupin gains after getting tentative USFDA approval for Amifampridine tablets 10 mg

Amifampridine Tablets, 10 mg, are bioequivalent to Firdapse Tablets, 10 mg, from Catalyst ...

Read more

17 Mar 2025 10:44

News

Lupin receives USFDA tentative approval for Amifampridine Tablets

Lupin has received tentative approval from the United States Food and Drug Administration ...

Read more

17 Mar 2025 13:36

News

Lupin launches Rivaroxaban drug in US

The newly launched drug is bioequivalent to Xarelto 2.5 mg from Janssen Pharmaceuticals, I...

Read more

10 Mar 2025 10:02

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Lupin Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Lupin Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 39,823 Cr while Market cap of Lupin Ltd is 95,369 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Lupin Ltd?

As of April 24, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1411.25. On the other hand, Lupin Ltd stock price is INR ₹2088.85.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions